{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:59:55Z","timestamp":1787918395123,"version":"build-2784847793"},"reference-count":38,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Australian Government Medical Research Future Fund","award":["2001877"],"award-info":[{"award-number":["2001877"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,30]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Many chemotherapy agents used to treat advanced cancer are inherently mucotoxic, causing breakdown of the gastrointestinal mucosa (gastrointestinal mucositis (GI-M)) and lead to a constellation of secondary complications including diarrhoea, malnutrition, anorexia, pain, fatigue and sleep disturbances. These symptoms are usually managed individually, leading to polypharmacy and its associated risks. The endocannabinoid system regulates numerous biological and behavioural processes associated with chemotherapy side effects, suggesting its modulation could control these symptoms. Therefore, the CANnabinoids in CANcer (CANCAN) therapy trial is a phase II, randomised, double-blind, placebo-controlled trial that aims to determine the efficacy of medicinal cannabis in minimising GI-M and its associated symptom burden.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>The CANCAN trial is being conducted at four Australian sites: the Royal Adelaide Hospital, the Queen Elizabeth Hospital, Flinders Medical Centre and the Lyell McEwin Hospital. Adults (n=176) diagnosed with a solid tumour or a haematological cancer scheduled to receive mucotoxic chemotherapy will be eligible. Participants will be randomised 1:1 to receive either the investigational product (IP) or placebo, both delivered as sublingual wafers. The active IP contains cannabidiol (300\u2009mg\/day) and \u0394<jats:sup>9<\/jats:sup>-tetrahydrocannabinol (5\u201320\u2009mg\/day, titrated by the participant). The primary outcome is GI-M burden, determined by the Mucositis Daily Questionnaire. Secondary and tertiary outcomes include overall symptom burden (Edmonton Symptom Assessment Scale), anorexia (Average Functional Assessment of Anorexia\/Cachexia Therapy), depression\/anxiety (Hospital Anxiety and Depression Scale), financial toxicity (Functional Assessment of Chronic Illness Therapy COmprehensive Score for financial Toxicity), quality of life (European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire), incidence of chemotherapy dose reductions\/modifications, cumulative dose of chemotherapy administered, incidence\/length of hospitalisation, the use of supportive care, and the cost-benefit of the IP. The CANCAN trial prioritises patient experiences by focusing on patient-reported outcome measures and administering medicinal cannabis during active treatment to prevent symptoms that occur secondary to mucositis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The protocol has been approved by Central Adelaide Local Health Network Human Research Ethics Committee (2022HRE00037). All participants will be required to provide written or digitally authorised informed consent. Trial results will be disseminated in peer-reviewed journals, and at scientific conferences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ACTRN12622000419763.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2024-089336","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T21:55:12Z","timestamp":1741038912000},"page":"e089336","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Medicinal CANnabis (CBD\/THC) to prevent the symptoms and side effects of chemotherapy in people with advanced CANcer (CANCAN): protocol for a phase II, randomised, double-blind, placebo-controlled trial"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-6925","authenticated-orcid":false,"given":"Olivia M","family":"Bellas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7199-5733","authenticated-orcid":false,"given":"Sepehr","family":"Shakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-8855","authenticated-orcid":false,"given":"Gregory B","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zannettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David T","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganessan","family":"Kichenadasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarosalv","family":"Boublik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Louise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-8674","authenticated-orcid":false,"given":"Julie","family":"Marker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Cambareri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-2693","authenticated-orcid":false,"given":"Timothy","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6613-3661","authenticated-orcid":false,"given":"Hannah R","family":"Wardill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025040100150643000_15.3.e089336.1","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s00520-019-04892-0","article-title":"Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines","volume":"27","author":"Bowen","year":"2019","journal-title":"Support Care Cancer"},{"key":"2025040100150643000_15.3.e089336.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy145"},{"key":"2025040100150643000_15.3.e089336.3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/0973-1075.84527","article-title":"Individualized interventional pain management technique in early stage of cancer pain: a desirable protocol for improving quality of life","volume":"17","author":"Bhatnagar","year":"2011","journal-title":"Indian J Palliat Care"},{"key":"2025040100150643000_15.3.e089336.4","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1007\/s00520-020-05759-5","article-title":"Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: a population-based study","volume":"29","author":"Suh","year":"2021","journal-title":"Support Care Cancer"},{"key":"2025040100150643000_15.3.e089336.5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.7861\/fhj.2019-0048","article-title":"Establishing a service to tackle problematic polypharmacy","volume":"7","author":"Bennett","year":"2020","journal-title":"Future Healthc J"},{"key":"2025040100150643000_15.3.e089336.6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5694\/mja2.50244","article-title":"Polypharmacy among older Australians, 2006-2017: a population-based study","volume":"211","author":"Page","year":"2019","journal-title":"Med J Aust"},{"key":"2025040100150643000_15.3.e089336.7","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/agm2.12051","article-title":"Polypharmacy in elderly cancer patients: Challenges and the way clinical pharmacists can contribute in resource-limited settings","volume":"2","author":"Shrestha","year":"2019","journal-title":"Aging Med (Milton)"},{"key":"2025040100150643000_15.3.e089336.8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.681417","article-title":"Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies","volume":"12","author":"Dahlgren","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025040100150643000_15.3.e089336.9","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1007\/s00520-019-04893-z","article-title":"The pathogenesis of mucositis: updated perspectives and emerging targets","volume":"27","author":"Bowen","year":"2019","journal-title":"Support Care Cancer"},{"key":"2025040100150643000_15.3.e089336.10","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.715506","article-title":"Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease","volume":"12","author":"Sultan","year":"2021","journal-title":"Front Physiol"},{"key":"2025040100150643000_15.3.e089336.11","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.679396","article-title":"Gut Microbiota in NSAID Enteropathy: New Insights From Inside","volume":"11","author":"Wang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2025040100150643000_15.3.e089336.12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41416-023-02466-w","article-title":"Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges","volume":"130","author":"Wardill","year":"2024","journal-title":"Br J Cancer"},{"key":"2025040100150643000_15.3.e089336.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.07.028"},{"key":"2025040100150643000_15.3.e089336.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034301","article-title":"Effects of medical and non-medical cannabis use in older adults: protocol for a scoping review","volume":"10","author":"Wolfe","year":"2020","journal-title":"BMJ Open"},{"key":"2025040100150643000_15.3.e089336.15","doi-asserted-by":"crossref","first-page":"105302","DOI":"10.1016\/j.phrs.2020.105302","article-title":"Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities","volume":"163","author":"Lal","year":"2021","journal-title":"Pharmacol Res"},{"key":"2025040100150643000_15.3.e089336.16","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/nmo.12931","article-title":"The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease","volume":"28","author":"Hasenoehrl","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"2025040100150643000_15.3.e089336.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.10.006"},{"key":"2025040100150643000_15.3.e089336.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.05.018"},{"key":"2025040100150643000_15.3.e089336.19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","article-title":"Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial","volume":"31","author":"Grimison","year":"2020","journal-title":"Ann Oncol"},{"key":"2025040100150643000_15.3.e089336.20","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2147\/IJWH.S401938","article-title":"Oral Tetrahydrocannabinol (THC):Cannabinoid (CBD) Cannabis Extract Adjuvant for Reducing Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial","volume":"15","author":"Sukpiriyagul","year":"2023","journal-title":"Int J Womens Health"},{"key":"2025040100150643000_15.3.e089336.21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jamaoto.2018.0486","article-title":"Association of Marijuana Use With Psychosocial and Quality of Life Outcomes Among Patients With Head and Neck Cancer","volume":"144","author":"Zhang","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2025040100150643000_15.3.e089336.22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq727"},{"key":"2025040100150643000_15.3.e089336.23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.2.567"},{"key":"2025040100150643000_15.3.e089336.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1847"},{"key":"2025040100150643000_15.3.e089336.25","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"key":"2025040100150643000_15.3.e089336.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01238.x"},{"key":"2025040100150643000_15.3.e089336.27","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2018.01969","article-title":"The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No \u201cStrain,\u201d No Gain","volume":"9","author":"Russo","year":"2018","journal-title":"Front Plant Sci"},{"key":"2025040100150643000_15.3.e089336.28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649555","article-title":"A Phase 2 Randomised Clinical Trial Assessing the Tolerability of Two Different Ratios of Medicinal Cannabis in Patients With High Grade Gliomas","volume":"11","author":"Schloss","year":"2021","journal-title":"Front Oncol"},{"key":"2025040100150643000_15.3.e089336.29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejim.2023.03.028","article-title":"Can we predict the treatment doses of THC and CBD and does it matter?","volume":"112","author":"Halamish","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025040100150643000_15.3.e089336.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.01.004"},{"key":"2025040100150643000_15.3.e089336.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06301-x"},{"key":"2025040100150643000_15.3.e089336.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020745","article-title":"Oral cannabinoid-rich THC\/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV)","volume":"8","author":"Mersiades","year":"2018","journal-title":"BMJ Open"},{"key":"2025040100150643000_15.3.e089336.33","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07312-y"},{"key":"2025040100150643000_15.3.e089336.34","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-019-0494-6"},{"key":"2025040100150643000_15.3.e089336.35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/joim.13627","article-title":"Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis","volume":"293","author":"Lo","year":"2023","journal-title":"J Intern Med"},{"key":"2025040100150643000_15.3.e089336.36","doi-asserted-by":"crossref","DOI":"10.1177\/2054358119828391","article-title":"A Review of Cannabis in Chronic Kidney Disease Symptom Management","volume":"6","author":"Ho","year":"2019","journal-title":"Can J Kidney Health Dis"},{"key":"2025040100150643000_15.3.e089336.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2526-5"},{"key":"2025040100150643000_15.3.e089336.38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11764-020-00924-5","article-title":"A core set of patient-reported outcomes for population-based cancer survivorship research: a consensus study","volume":"15","author":"Ramsey","year":"2021","journal-title":"J Cancer Surviv"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-089336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T07:16:31Z","timestamp":1743491791000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-089336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-089336"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-089336","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}